RIGEL PHARMACEUTICALS INC (RIGL) Fundamental Analysis & Valuation

NASDAQ:RIGL • US7665597024

Current stock price

25.96 USD
-0.14 (-0.54%)
At close:
25.96 USD
0 (0%)
After Hours:

This RIGL fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

6

1. RIGL Profitability Analysis

1.1 Basic Checks

  • RIGL had positive earnings in the past year.
  • In the past year RIGL had a positive cash flow from operations.
  • In the past 5 years RIGL reported 4 times negative net income.
  • In multiple years RIGL reported negative operating cash flow during the last 5 years.
RIGL Yearly Net Income VS EBIT VS OCF VS FCFRIGL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M -40M -60M

1.2 Ratios

  • RIGL has a Return On Assets of 46.72%. This is amongst the best in the industry. RIGL outperforms 98.84% of its industry peers.
  • RIGL has a better Return On Equity (96.34%) than 99.42% of its industry peers.
  • With an excellent Return On Invested Capital value of 63.44%, RIGL belongs to the best of the industry, outperforming 99.61% of the companies in the same industry.
Industry RankSector Rank
ROA 46.72%
ROE 96.34%
ROIC 63.44%
ROA(3y)-18.12%
ROA(5y)-18.4%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
RIGL Yearly ROA, ROE, ROICRIGL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200 400

1.3 Margins

  • RIGL has a Profit Margin of 40.17%. This is amongst the best in the industry. RIGL outperforms 97.49% of its industry peers.
  • The Operating Margin of RIGL (42.17%) is better than 99.03% of its industry peers.
  • Looking at the Gross Margin, with a value of 93.10%, RIGL belongs to the top of the industry, outperforming 93.62% of the companies in the same industry.
  • RIGL's Gross Margin has declined in the last couple of years.
Industry RankSector Rank
OM 42.17%
PM (TTM) 40.17%
GM 93.1%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.38%
GM growth 5Y-1.87%
RIGL Yearly Profit, Operating, Gross MarginsRIGL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -500 -1K -1.5K

6

2. RIGL Health Analysis

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), RIGL is creating value.
  • RIGL has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
RIGL Yearly Shares OutstandingRIGL Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M
RIGL Yearly Total Debt VS Total AssetsRIGL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

2.2 Solvency

  • Based on the Altman-Z score of -1.80, we must say that RIGL is in the distress zone and has some risk of bankruptcy.
  • RIGL's Altman-Z score of -1.80 is in line compared to the rest of the industry. RIGL outperforms 51.06% of its industry peers.
  • The Debt to FCF ratio of RIGL is 0.88, which is an excellent value as it means it would take RIGL, only 0.88 years of fcf income to pay off all of its debts.
  • RIGL's Debt to FCF ratio of 0.88 is amongst the best of the industry. RIGL outperforms 94.58% of its industry peers.
  • RIGL has a Debt/Equity ratio of 0.25. This is a healthy value indicating a solid balance between debt and equity.
  • RIGL's Debt to Equity ratio of 0.25 is on the low side compared to the rest of the industry. RIGL is outperformed by 66.34% of its industry peers.
  • Even though the debt/equity ratio score it not favorable for RIGL, it has very limited outstanding debt, so we won't put too much weight on the DE evaluation.
Industry RankSector Rank
Debt/Equity 0.25
Debt/FCF 0.88
Altman-Z -1.8
ROIC/WACC7.09
WACC8.95%
RIGL Yearly LT Debt VS Equity VS FCFRIGL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M

2.3 Liquidity

  • RIGL has a Current Ratio of 2.28. This indicates that RIGL is financially healthy and has no problem in meeting its short term obligations.
  • With a Current ratio value of 2.28, RIGL is not doing good in the industry: 73.50% of the companies in the same industry are doing better.
  • A Quick Ratio of 2.14 indicates that RIGL has no problem at all paying its short term obligations.
  • The Quick ratio of RIGL (2.14) is worse than 73.11% of its industry peers.
Industry RankSector Rank
Current Ratio 2.28
Quick Ratio 2.14
RIGL Yearly Current Assets VS Current LiabilitesRIGL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

2

3. RIGL Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 593.62% over the past year.
EPS 1Y (TTM)593.62%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%43.75%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%21.19%

3.2 Future

  • The Earnings Per Share is expected to decrease by -2.44% on average over the next years.
  • Based on estimates for the next years, RIGL will show a small growth in Revenue. The Revenue will grow by 6.25% on average per year.
EPS Next Y-36.48%
EPS Next 2Y-13.06%
EPS Next 3Y-8.59%
EPS Next 5Y-2.44%
Revenue Next Year-3.44%
Revenue Next 2Y4.1%
Revenue Next 3Y9.65%
Revenue Next 5Y6.25%

3.3 Evolution

RIGL Yearly Revenue VS EstimatesRIGL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 100M 200M 300M 400M
RIGL Yearly EPS VS EstimatesRIGL Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 5 -5

8

4. RIGL Valuation Analysis

4.1 Price/Earnings Ratio

  • Based on the Price/Earnings ratio of 3.98, the valuation of RIGL can be described as very cheap.
  • RIGL's Price/Earnings ratio is rather cheap when compared to the industry. RIGL is cheaper than 99.23% of the companies in the same industry.
  • The average S&P500 Price/Earnings ratio is at 25.23. RIGL is valued rather cheaply when compared to this.
  • Based on the Price/Forward Earnings ratio of 6.27, the valuation of RIGL can be described as very cheap.
  • Based on the Price/Forward Earnings ratio, RIGL is valued cheaper than 98.45% of the companies in the same industry.
  • RIGL is valuated cheaply when we compare the Price/Forward Earnings ratio to 23.28, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 3.98
Fwd PE 6.27
RIGL Price Earnings VS Forward Price EarningsRIGL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30 40 50

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, RIGL is valued cheaper than 99.23% of the companies in the same industry.
  • 99.23% of the companies in the same industry are more expensive than RIGL, based on the Price/Free Cash Flow ratio.
Industry RankSector Rank
P/FCF 6.91
EV/EBITDA 2.54
RIGL Per share dataRIGL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 5 10 15

4.3 Compensation for Growth

  • RIGL has a very decent profitability rating, which may justify a higher PE ratio.
  • RIGL's earnings are expected to decrease with -8.59% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-13.06%
EPS Next 3Y-8.59%

0

5. RIGL Dividend Analysis

5.1 Amount

  • No dividends for RIGL!.
Industry RankSector Rank
Dividend Yield 0%

RIGL Fundamentals: All Metrics, Ratios and Statistics

RIGEL PHARMACEUTICALS INC

NASDAQ:RIGL (3/20/2026, 8:20:51 PM)

After market: 25.96 0 (0%)

25.96

-0.14 (-0.54%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-03
Earnings (Next)05-04
Inst Owners91.09%
Inst Owner Change6.53%
Ins Owners3.09%
Ins Owner Change6.76%
Market Cap471.17M
Revenue(TTM)N/A
Net Income(TTM)113.30M
Analysts80
Price Target47.94 (84.67%)
Short Float %21.33%
Short Ratio9.18
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)46.05%
Min EPS beat(2)24.64%
Max EPS beat(2)67.46%
EPS beat(4)4
Avg EPS beat(4)188.12%
Min EPS beat(4)24.64%
Max EPS beat(4)592.43%
EPS beat(8)7
Avg EPS beat(8)242.36%
EPS beat(12)11
Avg EPS beat(12)181.29%
EPS beat(16)14
Avg EPS beat(16)138.58%
Revenue beat(2)2
Avg Revenue beat(2)11.07%
Min Revenue beat(2)10.05%
Max Revenue beat(2)12.08%
Revenue beat(4)4
Avg Revenue beat(4)12.62%
Min Revenue beat(4)9.15%
Max Revenue beat(4)19.17%
Revenue beat(8)7
Avg Revenue beat(8)10.41%
Revenue beat(12)11
Avg Revenue beat(12)14.43%
Revenue beat(16)12
Avg Revenue beat(16)11.18%
PT rev (1m)0%
PT rev (3m)3.68%
EPS NQ rev (1m)0%
EPS NQ rev (3m)17.09%
EPS NY rev (1m)0.23%
EPS NY rev (3m)1.14%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)3.4%
Revenue NY rev (1m)0.27%
Revenue NY rev (3m)0.78%
Valuation
Industry RankSector Rank
PE 3.98
Fwd PE 6.27
P/S 1.67
P/FCF 6.91
P/OCF 6.91
P/B 4.01
P/tB 5.11
EV/EBITDA 2.54
EPS(TTM)6.52
EY25.12%
EPS(NY)4.14
Fwd EY15.95%
FCF(TTM)3.75
FCFY14.46%
OCF(TTM)3.76
OCFY14.47%
SpS15.54
BVpS6.48
TBVpS5.08
PEG (NY)N/A
PEG (5Y)N/A
Graham Number30.83
Profitability
Industry RankSector Rank
ROA 46.72%
ROE 96.34%
ROCE 80.3%
ROIC 63.44%
ROICexc 854.98%
ROICexgc N/A
OM 42.17%
PM (TTM) 40.17%
GM 93.1%
FCFM 24.16%
ROA(3y)-18.12%
ROA(5y)-18.4%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.38%
GM growth 5Y-1.87%
F-Score7
Asset Turnover1.16
Health
Industry RankSector Rank
Debt/Equity 0.25
Debt/FCF 0.88
Debt/EBITDA 0.25
Cap/Depr 1.57%
Cap/Sales 0.01%
Interest Coverage 17.61
Cash Conversion 56.17%
Profit Quality 60.14%
Current Ratio 2.28
Quick Ratio 2.14
Altman-Z -1.8
F-Score7
WACC8.95%
ROIC/WACC7.09
Cap/Depr(3y)424.8%
Cap/Depr(5y)301.24%
Cap/Sales(3y)4.48%
Cap/Sales(5y)3%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)593.62%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%43.75%
EPS Next Y-36.48%
EPS Next 2Y-13.06%
EPS Next 3Y-8.59%
EPS Next 5Y-2.44%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%21.19%
Revenue Next Year-3.44%
Revenue Next 2Y4.1%
Revenue Next 3Y9.65%
Revenue Next 5Y6.25%
EBIT growth 1Y1151.72%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year546.96%
EBIT Next 3Y91.91%
EBIT Next 5Y95.89%
FCF growth 1Y286.79%
FCF growth 3Y80.89%
FCF growth 5YN/A
OCF growth 1Y418.44%
OCF growth 3Y74.92%
OCF growth 5YN/A

RIGEL PHARMACEUTICALS INC / RIGL Fundamental Analysis FAQ

What is the ChartMill fundamental rating of RIGEL PHARMACEUTICALS INC (RIGL) stock?

ChartMill assigns a fundamental rating of 5 / 10 to RIGL.


What is the valuation status for RIGL stock?

ChartMill assigns a valuation rating of 8 / 10 to RIGEL PHARMACEUTICALS INC (RIGL). This can be considered as Undervalued.


Can you provide the profitability details for RIGEL PHARMACEUTICALS INC?

RIGEL PHARMACEUTICALS INC (RIGL) has a profitability rating of 6 / 10.


How financially healthy is RIGEL PHARMACEUTICALS INC?

The financial health rating of RIGEL PHARMACEUTICALS INC (RIGL) is 6 / 10.